Enzo Biochem signs agreement with GeneNews for colorectal cancer test

Posted on: Thu, 19 Nov 2009 09:52:00 EST


Symbols: ENZ
Nov 19, 2009 (Datamonitor via COMTEX) --
ENZ | Quote | Chart | News | PowerRating -- Enzo Biochem, a US-based life sciences and biotechnology company, has entered into an agreement with GeneNews, a Canadian molecular diagnostics company, for exclusive rights to market GeneNews's ColonSentry, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

Enzo will undertake to validate and seek approval of the ColonSentry test pursuant to New York, New Jersey and Clinical Laboratory Improvement Act requirements, in addition to marketing, and securing third party reimbursement for the test. Terms were not disclosed.

Enzo has said that subject to regulatory and reimbursement approval, among others, it hopes to make the test available in the second half of 2010.

The test offers a novel, non-invasive option for determining an individual's current risk for colorectal cancer and helps prioritize patients at greater risk for the disease, said Enzo Biochem.

Kevin Krenitsky, president of Enzo Labs, said: "Enzo Labs's objective is to become a world-class provider of both routine and esoteric clinical tests, including molecular diagnostics, in line with the changing dynamics in health care. We are therefore pleased to join with GeneNews as its exclusive marketing partner in New York and New Jersey in making this product available to the medical communities we serve and their patients."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

For full details on Enzo Biochem Inc (ENZ) ENZ. Enzo Biochem Inc (ENZ) has Short Term PowerRatings at TradingMarkets. Details on Enzo Biochem Inc (ENZ) Short Term PowerRatings is available at This Link.